8 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 8, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Mucocutaneous Lymph Node Syndrome: new trials by email Literature Review of Mucocutaneous Lymph Node Syndrome trials Research Report on Mucocutaneous Lymph Node Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease IVIG, Aspirin, Firsekibart - Kawasaki Disease | Phase 2 / Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 90 | 2026-11-01 | 2026-10-22 |
| Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities atorvastatin of dose level 1, atorvastatin of dose level 2, atorvastatin of dose level 3 - Kawasaki Disease, Coronary Artery Abnormalities | Phase 3 | Recruiting | Children's Hospital of Fudan University | 9 | 2026-06-08 | 2026-06-16 |
| A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment ANAKINRA, Intravenous immunoglobulin - Kawasaki Disease | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 84 | 2023-10-20 | 2024-02-28 |
| Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease IVIG, Aspirin, Infliximab - Kawasaki Disease | Phase 3 | Withdrawn | Children's Hospital of Fudan University | 2020-10-01 | 2021-03-12 | |
| Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease IVIG, Aspirin, Prednisolone - Kawasaki Disease | Phase 3 | Completed | Children's Hospital of Fudan University | 3208 | 2020-01-15 | 2026-04-16 |
| KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) IVIG, Infliximab - Mucocutaneous Lymph Node Syndrome | Phase 3 | Completed | University of California, San Diego | 105 | 2017-02-17 | 2021-12-03 |
| Different Doses of IVIG for Kawasaki Disease IVIG (1g/kg,once), IVIG (1g/kg,twice), IVIG (2g/kg.once) - Kawasaki Disease | Phase 3 | Completed | Children's Hospital of Fudan University | 404 | 2014-01-01 | 2018-05-11 |
| A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prednisolone, immunoglobulin - Kawasaki Disease, Steroid | Phase 3 | Unknown | National Taiwan University Hospital | 100 | 2013-10-17 | 2017-06-27 |
| Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial Infliximab, IVIG - Kawasaki Disease | Phase 3 | Completed | Fudan University | 40 | 2013-01-01 | 2016-02-03 |
| Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH) - Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin | Phase 3 | Completed | Tanabe Pharma Corporation | 31 | 2012-05-01 | 2026-01-07 |
| Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Infliximab, Placebo - Kawasaki Disease | Phase 3 | Completed | University of California, San Diego | 196 | 2009-03-01 | 2014-11-24 |
| A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Sestamibi - Kawasaki Disease | Phase 3 | Completed | Lantheus Medical Imaging | 445 | 2005-08-01 | 2019-07-23 |
| Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Immune Globulin Intravenous (Human), 10% - Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Completed | Baxalta now part of Shire | 61 | 2002-06-25 | 2021-08-24 |
Immunologic Deficiency Syndromes (1) · Primary Immunodeficiency Diseases (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Cardiovascular Diseases (13) · Hemic and Lymphatic Diseases (13) · Lymphatic Diseases (13) · Skin Diseases (13) · Skin Diseases, Vascular (13) · Skin and Connective Tissue Diseases (13) · Vascular Diseases (13) · Vasculitis (13) · Autoimmune Diseases (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cytopenia (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1)
Immunoglobulins, Intravenous (7) · Infliximab (4) · Aspirin (3) · Prednisolone (2) · Immunoglobulins (1) · Interleukin 1 Receptor Antagonist Protein (1) · Interleukins (1) · Technetium Tc 99m Sestamibi (1) · acetylsalicylic acid lysinate (1) · gamma-Globulins (1)
Children's Hospital of Fudan University (5) · University of California, San Diego (2) · Assistance Publique - Hôpitaux de Paris (1) · Baxalta now part of Shire (1) · Fudan University (1) · Lantheus Medical Imaging (1) · National Taiwan University Hospital (1) · Tanabe Pharma Corporation (1)
China (6) · United States (4) · Taiwan (2) · Brazil (1) · Canada (1) · France (1) · Japan (1) · Philippines (1) · South Korea (1) · Thailand (1)
Adriana H. Tremoulet, M.D. (1) · Chen Chu, MD (1) · Fang Liu, MD (1) · Fang Liu, MD. (1) · Guoying Huang, MD. (1) · Guoying Huang, PHD (1) · Jane C Burns, M.D. (1) · Jane C Burns, MD (1) · Masaaki Mori, MD (1) · Mei-Hwan Wu, MD, PhD (1) · Ming-Tai Lin, MD, PhD (1) · Octavio Ramilo, M.D. (1) · Qi Zhu, MD, (1)
PMID 23305955, PMID 23901839, PMID 24572997, PMID 29386515, PMID 33600060, PMID 34715057, PMID 34895290, PMID 41985133